Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences Q3 revenue rises 29% to $239.5 million; 2025 guidance raised

Positive Impact 4 of 5 earnings Written later

Harmony Biosciences reported third-quarter 2025 net product revenue of $239.5 million, up 29% from $186.0 million a year earlier, and GAAP net income of $50.9 million, or $0.87 per diluted share, versus $0.79 a year earlier. The company raised its full-year 2025 net product revenue guidance to $845-$865 million from $820-$860 million, though its research and development expenses rose 117% to $55.0 million, including a $15.0 million charge tied to a ZYN002 milestone.

Key points

  • Q3 2025 net product revenue of $239.5 million, up from $186.0 million in Q3 2024
  • GAAP net income of $50.9 million, or $0.87 per diluted share, versus $0.79 in Q3 2024
  • 2025 net product revenue guidance raised to $845-$865 million from $820-$860 million
  • ZYN002 phase 3 RECONNECT study in Fragile X syndrome missed its primary endpoint; the 22q11.2 deletion syndrome program is paused

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECNov 4, 2025, 8:05 AM ET
Accession number0001104659-25-105942

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.